Histudy is a education website template. You can customize all.
A monoclonal antibody called Daratumumab (trade name: Darzalex) was created by Janssen Biotech, a division of Johnson & Johnson. The U.S. Food and Drug Administration originally approved it in November 2015 as a treatment for multiple myeloma in patients who had already tried at least three other lines of treatment. Daratumbabab has transformed multiple myeloma treatment since it was approved, and it has now acquired further approvals for a number of applications, reaffirming its place as a prominent therapeutic choice in the management of this challenging condition. It has been very effective in combating multiple myeloma. Although certain symptoms are present, its efficacy is still quite good. Daratumumab's ability to provide positive results in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation has been further supported by the Maia trial, a crucial study in this area. Daratumumab works by targeting CD38, a cell surface glycoprotein that is abundantly expressed in malignant plasma cells. This causes antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and direct activation of death. Daratumumab is becoming more and more important as a good therapeutic choice for people with multiple myeloma as a result of a thorough understanding of its effectiveness, symptoms, and mechanism of action.
By: Aryan Marri